Ergoteles LLC Fate Therapeutics Inc Transaction History

Ergoteles LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $147,136 - $203,703	30,911 New	30,911 $147,000
Q1 2022 May 13, 2022	SELL	$29.67 - $60.28 $1.4 Million - $2.83 Million	-47,026 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $2.25 Million - $3.03 Million	47,026 New	47,026 $2.75 Million
Q3 2021 Nov 15, 2021	SELL	$59.27 - $95.73 $210,645 - $340,224	-3,554 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$67.25 - $92.52 $1.06 Million - $1.46 Million	-15,746 Reduced 81.59%	3,554 $308,000
Q1 2021 May 12, 2021	BUY	$72.16 - $117.4 $1.39 Million - $2.27 Million	19,300 New	19,300 $1.59 Million

176

113M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $123M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.